Santen Pharmaceutical Co Stock Performance
| SNPHY Stock | USD 10.61 0.48 4.33% |
The entity has a beta of -0.085, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Santen Pharmaceutical are expected to decrease at a much lower rate. During the bear market, Santen Pharmaceutical is likely to outperform the market. At this point, Santen Pharmaceutical has a negative expected return of -0.19%. Please make sure to validate Santen Pharmaceutical's total risk alpha, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Santen Pharmaceutical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Santen Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's technical indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 62.9 B | |
| Total Cashflows From Investing Activities | -35.2 B |
Santen |
Santen Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 1,232 in Santen Pharmaceutical Co on August 31, 2024 and sell it today you would lose (171.00) from holding Santen Pharmaceutical Co or give up 13.88% of portfolio value over 90 days. Santen Pharmaceutical Co is currently producing negative expected returns and takes up 3.2451% volatility of returns over 90 trading days. Put another way, 28% of traded pink sheets are less volatile than Santen, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Santen Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Santen Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Santen Pharmaceutical Co, and traders can use it to determine the average amount a Santen Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0572
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SNPHY |
Estimated Market Risk
| 3.25 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Santen Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Santen Pharmaceutical by adding Santen Pharmaceutical to a well-diversified portfolio.
Santen Pharmaceutical Fundamentals Growth
Santen Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Santen Pharmaceutical, and Santen Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Santen Pink Sheet performance.
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 388.22 M | |||
| Price To Earning | 14.22 X | |||
| Price To Book | 1.39 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 266.26 B | |||
| EBITDA | 53.91 B | |||
| Cash And Equivalents | 69.53 B | |||
| Cash Per Share | 176.84 X | |||
| Total Debt | 32.93 B | |||
| Debt To Equity | 0.1 % | |||
| Book Value Per Share | 780.63 X | |||
| Cash Flow From Operations | 46.04 B | |||
| Earnings Per Share | 0.47 X | |||
| Total Asset | 459.98 B | |||
| Retained Earnings | 230.22 B | |||
| Current Asset | 156.63 B | |||
| Current Liabilities | 50.32 B | |||
About Santen Pharmaceutical Performance
Evaluating Santen Pharmaceutical's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Santen Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Santen Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people.Things to note about Santen Pharmaceutical performance evaluation
Checking the ongoing alerts about Santen Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Santen Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Santen Pharmaceutical generated a negative expected return over the last 90 days | |
| Santen Pharmaceutical has high historical volatility and very poor performance |
- Analyzing Santen Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Santen Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Santen Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Santen Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Santen Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Santen Pharmaceutical's pink sheet. These opinions can provide insight into Santen Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Santen Pink Sheet Analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.